✦ LIBER ✦

An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma

✍ Scribed by Katsuhiro Miura; Kazuhiro Takei; Sumiko Kobayashi; Satomi Kiso; Yukio Hirabayashi; Atsuko Hojo; Hitomi Kodaira; Mai Yagi; Daisuke Kurita; Yujin Kobayashi; Toshitake Tanaka; Noriyoshi Iriyama; Yoshihiro Hatta; Yoshimasa Kura; Tetsuo Yamazaki; Umihiko Sawada; Jin Takeuchi

Book ID: 107619328
Publisher: Carden Jennings Publishing
Year: 2011
Tongue: English
Weight: 234 KB
Volume: 94
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-011-0884-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erratum to: An effective salvage treatme

Erratum to: An effective salvage treatment using ifosfamide, etoposide, cytarabine, dexamethasone, and rituximab (R-IVAD) for patients with relapsed or refractory aggressive B-cell lymphoma

✍ Katsuhiro Miura; Kazuhiro Takei; Sumiko Kobayashi; Satomi Kiso; Yukio Hirabayash 📂 Article 📅 2011 🏛 Carden Jennings Publishing 🌐 English ⚖ 86 KB

Oxaliplatin-based chemotherapy (dexameth

Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin) ± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma

✍ Luigi Rigacci; Alberto Fabbri; Benedetta Puccini; Ida Chitarrelli; Annalisa Chia 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB

Phase II study of a salvage regimen usin

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

✍ Yasuhiro Oki; Michinori Ogura; Harumi Kato; Ako Kikuchi; Hirofumi Taji; Yoshitoy 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB

Ifosfamide, etoposide, cytarabine, and d

Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas

✍ P. Schütt; J. Passon; P. Ebeling; A. Welt; S. Müller; K. Metz; T. Moritz; S. See 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 594 KB

Bortezomib in combination with rituximab

Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma

✍ Elstrom, Rebecca L.; Andemariam, Biree; Martin, Peter; Ruan, Jia; Shore, Tsipora 📂 Article 📅 2012 🏛 Informa plc 🌐 English ⚖ 224 KB

Cladribine combined with rituximab (R-2-

Cladribine combined with rituximab (R-2-CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B-cell non-Hodgkin lymphoma

✍ Hirokazu Nagai; Michinori Ogura; Shigeru Kusumoto; Naoto Takahashi; Motoko Yamag 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB